---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000064"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-11-22T23:59:59+00:00"
generated_at: "2026-05-29T19:32:11.328073+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lexicon cuts workforce 60%, halts commercial ops after FDA setback on ZYNQUISTA

## Summary
- FDA issued 'deficiencies preclude discussion' letter for ZYNQUISTA (sotagliflozin) NDA in type 1 diabetes and CKD.
- Company eliminating commercial operations and reducing workforce by approximately 60%.
- Estimated pre-tax charges of $9M–$10.5M for severance and employee costs, mostly cash in Q1 2025.
- Company cites need to preserve cash and focus resources on clinical development pipeline.

## SEC filing metadata
- accession: 0001062822-24-000064
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000064/0001062822-24-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000064/lxrx-20241122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000064
- JSON: https://secwatch.observer/filing/0001062822-24-000064.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000064.txt

## Key facts
- Restructurings & Charges
  LEXICON PHARMACEUTICALS, INC. announced a restructuring with charges of $9.0 million to $10.5 million affecting commercial operations and across all functions (reduce our workforce by approximately sixty percent).
  - Type: restructuring
  - Charge: $9.0 million to $10.5 million
  - Affected area: commercial operations and across all functions
  - Headcount: reduce our workforce by approximately sixty percent
  source text: On November 22, 2024 we determined to eliminate our commercial operations and rationalize resources across all functions in order to preserve cash and focus our resources on advancing our clinical development pipeline. In connection with such determination, we intend to implement a reduction in force which will reduce our workforce by approximately sixty percent. We estimate that we will incur an aggregate of approximately $9.0 million to $10.5 million in pre-tax charges in connection with severance and other employee costs associated with the reduction in force, most of which will be paid in the first quarter of 2025 and all of which are expected to be cash expenditures.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000064/0001062822-24-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.